Citations

Showing 10 of 108152 citations.

Diaphragm dysfunction in severe COVID‐19 as determined by neuromuscular ultrasound
Farr, Ellen , Wolfe, Alexis R. , Deshmukh, Swati , Rydberg, Leslie , Soriano, Rachna, Boon, Andrea J. , Wolfe, Lisa F. , Franz, Colin K. , Franz, Colin K , Walter, James McCauley

Mayo Clinic

Annals of Clinical and Translational Neurology | July 11, 2021 | Volume: 8 | Issue: 8 | Pages: 1745-1749

10.1002/acn3.51416 | PMID 34247452 Get It

Abstract Many survivors from severe coronavirus disease 2019 (COVID‐19) suffer from persistent dyspnea and fatigue long after resolution of the active infection. In a cohort of 21 consecutive severe post‐COVID‐19 survivors admitted to an inpatient rehabilitation hospital, 16 (76%) of them had at least one sonographic abnormality of diaphragm muscle structure or function. This corresponded to a significant reduction in diaphragm muscle contractility as represented by thickening ratio (muscle thickness at maximal inspiration/end‐expiration) for the post‐COVID‐19 compared to non‐COVID‐19 cohorts. These findings may shed new light on neuromuscular respiratory dysfunction as a contributor to prolonged functional impairments after hospitalization for post‐COVID‐19.
Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis
Alnahhas, Iyad , Alsawas, Mouaz , Raval, Raju R. , Ong, Shirley, Giglio, Pierre , Murad, Mohammad Hassan, Alsawas, Mouaz , Rayi, Appaji , Palmer, Joshua D. , Murad, M. Hassan , Puduvalli, Vinay K.

Mayo Clinic

Neuro-Oncology Advances | July 10, 2021 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdab095 | PMID 34258581 Get It

Participation of persons with dementia and their caregivers in research
Frank, Lori , Jennings, Lee A. , Petersen, Ronald C. , Majid, Tabassum , Schicker, Lonni, Karlawish, Jason , Gilmore‐Bykovskyi, Andrea L

Mayo Clinic

Journal of the American Geriatrics Society | July 10, 2021 | Volume: 69 | Issue: 7 | Pages: 1784-1792

10.1111/jgs.17340 | PMID 34245586 Get It

Abstract Background The National Institute on Aging, in conjunction with the Department of Health and Human Services as part of the National Alzheimer's Project Act, convened a 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and their Caregivers . This review article addresses research participation by persons living with dementia (PLWD) and their care partners in two different ways: as research participants with input on outcomes studied and as engaged research partners. Results This article summarizes each of the topics presented at this Summit session, followed by reflection from the session panelists. Lee Jennings examined collection of outcomes directly from PLWD and the potential for individualized outcomes to enhance measurement in intervention trials. Ron Petersen discussed the impact of nomenclature on research and clinical care, and how and why investigators should be mindful of the connection between dementia nomenclature and the conduct of dementia research. Tabassum Majid examined strategies for engagement in research, including specific examples of involving PLWD and their care partners (including staff in assisted living and skilled nursing facilities), and the potential for this research engagement to improve our understanding of interventions in dementia. Conclusions Research participation by PLWD and their care partners is evolving. This review summarizes three areas of opportunity and steps for researchers to work with PLWD and their care partners to design and conduct research that enhances knowledge based on what we learn from PLWD and their care partners, and creates knowledge with them.
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate‐risk Hodgkin lymphoma treated with chemo‐radiation therapy: FDG‐PET parameter analysis in a subgroup from COG AHOD0031
Milgrom, Sarah A. , Kim, Ji‐Hyun , Chirindel, Alin, Kim, Jongho , Pei, Qinglin , Chen, Lu , Buxton, Allen, Kessel, Sandy, Leal, Jeffrey P. , McCarten, Kathleen M. , Schwartz, Cindy L. , Kelly, Kara M. , Hoppe, Bradford S , Wolden, Suzanne , Hoppe, Bradford S. , Wolden, Suzanne L. , Friedman, Debra L. , Cho, Steve Y.

Mayo Clinic

Pediatric Blood & Cancer | July 10, 2021 | Volume: 68 | Issue: 9 | Pages: No page available

10.1002/pbc.29212 | PMID 34245210 Get It

AbstractBackgroundPositron emission tomography (PET)‐based measures of baseline total‐body tumor burden may improve risk stratification in intermediate‐risk Hodgkin lymphoma (HL).Materials and methodsEvaluable patients were identified from a cohort treated homogeneously with the same combined modality regimen on the Children's Oncology Group AHOD0031 study. Eligible patients had high‐quality baseline PET scans. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were each measured based on 15 thresholds for every patient. Univariate and multivariable Cox regression and Kaplan–Meier survival analyses assessed for an association of MTV and TLG with event‐free survival (EFS).ResultsFrom the AHOD0031 cohort (n = 1712), 86 patients were identified who (i) were treated with four cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide (ABVE‐PC) chemotherapy followed by involved field radiotherapy, and (ii) had a baseline PET scan that was amenable to quantitative analysis. Based on univariate Cox regression analysis, six PET‐derived parameters were significantly associated with EFS. For each of these, Kaplan–Meier analyses and the log‐rank test were used to compare patients with highest tumor burden (i.e., highest 15%) to the remainder of the cohort. EFS was significantly associated with all six PET parameters (all p < .029). In a multivariable model controlling for important covariates including disease bulk and response to chemotherapy, MTV2BP was significantly associated with EFS (p = .012).ConclusionMultiple baseline PET‐derived volumetric parameters were associated with EFS. MTV2BP was highly associated with EFS when controlling for disease bulk and response to chemotherapy. Incorporation of baseline MTV into risk‐based treatment algorithms may improve outcomes in intermediate‐risk HL.
Clinical predictors and impact of postoperative mean gradient on outcome after transcatheter edge‐to‐edge mitral valve repair
Oğuz, Didem , Padang, Ratnasari , Mankad, Sunil , Reeder, Guy S., Eleid, Mackram F. , Rihal, Charanjit S. , Thaden, Jeremy J. , Mankad, Sunil V., Eleid, Mackram F , Pislaru, Sorin V. , Nkomo, Vuyisile T. , Alkhouli, Mohamad , Guerrero, Mayra , Rihal, Charanjit S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | July 10, 2021 | Volume: 98 | Issue: 6 | Pages: No page available

10.1002/ccd.29867 | PMID 34245208 Get It

AbstractBackgroundThe predictors and clinical significance of increased Doppler‐derived mean diastolic gradient (MG) following transcatheter edge‐to‐edge mitral valve repair (MVTEER) remain controversial.ObjectiveWe sought to examine baseline correlates of Doppler‐derived increased MG post‐MVTEER and its impact on intermediate‐term outcomes.MethodsPatients undergoing MVTEER were analyzed retrospectively. Post‐MVTEER increased MG was defined as >5 mmHg or aborted clip implantation due to increased MG intraprocedurally. Baseline MG and 3D‐guided mitral valve area (MVA) by planimetry were retrospectively available in 233 and 109 patients.Results243 patients were included; 62 (26%) had MG > 5 mmHg post‐MVTEER or aborted clip insertion, including 7 (11%) that had aborted clip implantation. Mortality occurred in 63 (26%) during a median follow up of 516 days (IQR 211, 1021). Increased post‐MVTEER MG occurred more frequently in females (44% vs. 16%, p < 0.001), those with baseline MVA <4.0 cm2 (71% vs. 16%), baseline MG ≥4 mmHg (61% vs. 20%), or multiple clips implanted (33% vs. 21%, p = 0.04). Increased post‐MVTEER MG was associated with increased subsequent mortality compared to those with normal gradient (HR 1.91 95% CI 1.15–3.18 p = 0.016) as was aborted clip insertion compared to all others (HR 5.23 95% CI 2.06–13.28 p < 0.001).ConclusionsSmaller baseline MVA and increased baseline MG are associated with increased MG post‐MVTEER and patients with a Doppler‐derived post‐MVTEER MG >5 mmHg suffered excess subsequent mortality. In high risk patients considered for MVTEER, identification of those at risk of iatrogenic mitral stenosis with MVTEER is important as they may be optimally treated with alternate surgical or transcatheter therapies.
Use of telehealth in home nutrition support: Challenges and advantages
Mundi, Manpreet S. , Elfadil, Osman Mohamed , Bonnes, Sara L. , Salonen, Bradley R. , Mohamed Elfadil, Osman , Hurt, Ryan T. , Mundi, Manpreet S

Mayo Clinic

Nutrition in Clinical Practice | July 10, 2021 | Volume: 36 | Issue: 4 | Pages: 775-784

10.1002/ncp.10736 | PMID 34245465 Get It

Abstract Coronavirus disease 2019 (COVID‐19), after initially being detected in Wuhan, China in late 2019, quickly spread to most regions of the world, meeting World Health Organization criteria for a pandemic. Social distancing along with other measures implemented to control spread had a drastic impact on the provision of healthcare including deferred elective procedures and surgeries as well as delayed care and evaluation for emergent diagnoses such as heart attacks and strokes. In the home nutrition practice, patients began to delay routine laboratory tests and were canceling or deferring annual visits. Our group soon began to rapidly deploy telehealth to meet the needs of the home nutrition patients. Telehealth is not a new concept with descriptions of healthcare being provided at a distance with the use of telephone in the 1870s. However, widespread adoption has been limited because of regulation (licensure, prescriptions, credentialing, and privileges), lack of reimbursement, as well as adoption and availability of technology needed to carry out telehealth visits. As regulations and limits on reimbursements were waived during COVID‐19 pandemic, our home nutrition practice began to evaluate core components of the care we provide for our patients and assess which could be successfully transitioned to telehealth. In addition to the history and regulation of telehealth, the current manuscript provides details regarding successful implementation of telehealth visits such as change management, selection of telehealth platform, scheduling and logistics, as well as carrying out the virtual visit including history and physical exam.
Management of Lytic Bone Disease in Lymphoplasmacytic Lymphoma: A Case Report and Review of the Literature
Baksh, Mizba , Jiang, Liuyan , Bhatia, Unnati , Alegria, Victoria R., Sher, Taimur , Chanan‐Khan, Asher , Baksh, Mizba , Roy, Vivek , Ailawadhi, Sikander , Parrondo, Ricardo D

Mayo Clinic

No container title available | July 10, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.162592069.98366479/v1 Get It

Waldenström Macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL and management is poorly understood. We describe a case of an 81-year-old woman with LPL who presented with LBL and was successfully treated with chemoimmunotherapy.
Retrosigmoid Craniectomy and Suprameatal Drilling—3-Dimensionally Printed Microneurosurgical Simulation: 2-Dimensional Operative Video
Martínez, Jaime L., Damon, Aaron , Domingo, Ricardo A. , Valero‐Moreno, Fidel, Quiñones‐Hinojosa, Alfredo , Domingo, Ricardo A

Mayo Clinic

Operative Neurosurgery | July 10, 2021 | Volume: 21 | Issue: 4 | Pages: E355-E356

10.1093/ons/opab238 | PMID 34245154 Get It

Abstract Neurosurgical training is being challenged by rigorous work-hour restrictions and the COVID-19 pandemic. 1 Now, more than ever, surgical simulation plays a pivotal role in resident education and psychomotor skill development. Three-dimensional (3D) printing technologies enable the construction of inexpensive, patient-specific, anatomically accurate physical models for a more convenient and realistic simulation of complex skull base approaches in a safe environment. 2 All stages of the surgical procedure can be simulated, from positioning and exposure to deep microdissection, which has an unparalleled educational value. The complex approach-specific anatomy, narrow working angles, and pathoanatomic relationships can be readily explored from the surgeon's perspective or point of view. 2,3 Furthermore, different thermoplastic polymers can be utilized to replicate the visual and tactile feedback of bone (cortical/cancellous), neurological, and vascular tissues. 4 Retrosigmoid craniectomies are widely used in neurosurgery with various applications, including microvascular decompressions in patients with trigeminal neuralgia. 5-7 Removal of the suprameatal tubercle (SMT) extends the retrosigmoid approach superiorly to the middle fossa and Meckel's cave, and anteriorly to the clivus. 8,9 This maneuver may be necessary in patients with prominent SMTs obstructing the view of the trigeminal nerve and in patients with a more anterosuperior neurovascular conflict. This video illustrates a microsurgical training tool for learning and honing the technique of retrosigmoid craniectomy and suprameatal drilling using an affordable (29.00 USD) biomimetic 3D-printed simulator that closely recapitulates not only the anatomy but also the tactile feedback of drilling and manipulating neurological tissues (see Table and Graph 1; minute 07:11) as it happens at the time of surgery.
Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Hurley, Rachel M. , McGehee, Cordelia D. , Nesic, Ksenija , Weiskittel, Taylor M. , Kelly, Rebecca L. , Venkatachalam, Annapoorna , Hou, Xiaonan , Pathoulas, Nicholas M. , Meng, X. Wei, Kondrashova, Olga , Schneider, Paula A., Flatten, Karen S., Peterson, Kevin L. , Becker, Marc A., Southey, Melissa S, Harding, Thomas C., McNeish, Iain A. , Wagner, Jill M., Wakefield, Matthew J. , Scott, Clare L. , Hendrickson, Andrea E. Wahner , Karnitz, Larry M., Swisher, Elizabeth M. , Weroha, S. John , Lin, Kevin K. , Dobrovic, Alexander , Ross, Christian A, Haluska, Paul , Kaufmann, Scott H , McNeish, Iain A , Swisher, Elizabeth M , Wakefield, Matthew J , Scott, Clare L , Kondrashova, Olga , Correia, Cristina , Radke, Marc R. , Wong, Ee Ming , Lin, Kevin , Roß, Christian , Li, Hu , Kaufmann, Scott H.

Mayo Clinic

NAR Cancer | July 10, 2021 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/narcan/zcab028 | PMID 34316715 Get It

Abstract Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. RAD51C is a less commonly studied ovarian cancer susceptibility gene whose promoter is sometimes methylated, leading to homologous recombination (HR) deficiency and PARPi sensitivity. For this study, the PARPi-sensitive patient-derived ovarian cancer xenograft PH039, which lacks HR gene mutations but harbors RAD51C promoter methylation, was selected for PARPi resistance by cyclical niraparib treatment in vivo. PH039 acquired PARPi resistance by the third treatment cycle and grew through subsequent treatment with either niraparib or rucaparib. Transcriptional profiling throughout the course of resistance development showed widespread pathway level changes along with a marked increase in RAD51C mRNA, which reflected loss of RAD51C promoter methylation. Analysis of ovarian cancer samples from the ARIEL2 Part 1 clinical trial of rucaparib monotherapy likewise indicated an association between loss of RAD51C methylation prior to on-study biopsy and limited response. Interestingly, the PARPi resistant PH039 model remained platinum sensitive. Collectively, these results not only indicate that PARPi treatment pressure can reverse RAD51C methylation and restore RAD51C expression, but also provide a model for studying the clinical observation that PARPi and platinum sensitivity are sometimes dissociated.
Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma
Kaddoura, Marcella , Dingli, David , Buadi, Francis K. , Lacy, Martha Q. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Lust, John A., Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Dispenzieri, Angela , Fonder, Amie , Leung, Nelson , Kourelis, Taxiarchis , Broski, Stephen M , Rajkumar, S Vincent , Kumar, Shaji K , Tschautscher, Marcella , Buadi, Francis K , Dingli, David , Lin, Yi , Gertz, Morie A. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I. , Broski, Stephen M. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | July 10, 2021 | Volume: 5 | Issue: 13 | Pages: 2753-2759

10.1182/bloodadvances.2020004131 | PMID 34242392 Get It

Abstract Multiple myeloma (MM) is a heterogeneous disease that may be evaluated by a broad array of imaging and laboratory techniques to measure disease activity and predict prognosis. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning has been shown to be predictive of patient outcomes throughout the disease course. We sought to corroborate these findings by examining the prognostic impact of PET/CT scanning in the posttransplant setting. We retrospectively analyzed PET/CT scans in 229 MM patients receiving an autologous stem cell transplant (ASCT) near day 100, and correlated these findings with time to progression(TTP) and overall survival (OS) to assess the impact of day 100 PET/CT scan findings as an independent prognostic factor. The median OS for the entire cohort was 61.5 months (95% confidence interval [CI], 49-75) and the median TTP was 18.5 months (95% CI, 15.4-21.8). Among patients with abnormal day 100 PET findings (PET+), median TTP was 12.4 months vs 24 months among those with normal PET findings (PET−) (P &lt; .0001). The median OS in the PET+ group was 46 months compared with 99 months in the PET− group (P &lt; .0001). We conclude that an abnormal PET/CT scan near day 100 post-ASCT is predictive of shorter TTP and OS, with prognostic significance retained after adjusting for disease response and other prognostic variables in MM.